AUTHOR OF THIS BLOG

DR ANTHONY MELVIN CRASTO, WORLDDRUGTRACKER

Total Synthesis and Biological Studies of TMC-205 and Analogues as Anticancer Agents and Activators of SV40 Promoter

 Uncategorized  Comments Off on Total Synthesis and Biological Studies of TMC-205 and Analogues as Anticancer Agents and Activators of SV40 Promoter
Jun 242014
 
Abstract Image
TMC 205
6-[3-Methyl-1(E),3-butadienyl]-1H-indole-3-carboxylic acid
C14 H13 N O2
227.2585
Mitsubishi Tanabe Pharma (Innovator) now in biological testing
TMC-205 is a natural fungal metabolite with antiproliferative activity against cancer cell lines. The light- and air-sensitivity prevented in-depth exploitation of this novel indole derivative. Herein, we report the first synthesis of TMC-205. On the basis of its reactivity with reactive oxygen species, we developed air-stable analogues of TMC-205. These analogues are 2–8-fold more cytotoxic than TMC-205 against HCT-116 colon cancer cell line. Importantly, at noncytotoxic dose levels, these analogues activated the transcription of luciferase reporter gene driven by simian virus 40 promoter (SV40). Further, these small molecules also inhibit firefly luciferase, presumably by direct interaction.
Total Synthesis and Biological Studies of TMC-205 and Analogues as Anticancer Agents and Activators of SV40 Promoter
Department of Chemistry, University of Pittsburgh, 219 Parkman Avenue, Pittsburgh, Pennsylvania 15260, United States
ACS Med. Chem. Lett., Article ASAP
DOI: 10.1021/ml500025p

SYNTHESIS…………..http://pubs.acs.org/doi/suppl/10.1021/ml500025p/suppl_file/ml500025p_si_001.pdf

Synthesisof TMC-205 (1):MeOH (1.5 mL) and aqueous
NaOH (4 M, 2.5 mL) were added to a 25-mL oven-driedround-
bottomed flask containing6(20 mg, 0.080 mmol) un-der an open atmosphere at 23°C
. The resulting solution was
covered from light and stirred in an 80°Coil bath for 2.25 h. The solution was then cooled to 23°C
, and steps
subsequent to cooling were performed in a dark environment. The solution was washed with CH2Cl2
(1 mL), and
then the aqueous layer was acidified with KHSO4
(3 M, 10 mL). The aqueous layerwas ex
tracted with EtOAc(10 mL×3). The combined organic layers were dried over Na2SO4
, filtered, and concentrated under reduced
pressure using a rotary evaporator (T
water bath= 30°C) to afford 16 mg of TMC-205 (1)
as a pale yellow solid
(88% yield, >
95% purity).
Data for TMC-205 (1):
Rf= 0.24 (40% EtOAc in hexanes);
IR (film):νmax
= 3432 (broad, O-H), 2920,2851,1644 (C=O), 1528, 1451, 1349 cm-1;
1H NMR (500 MHz, 293K, CD3OD):δ
= 7.99 (d,J= 8.3 Hz, 1H, 4-H), 7.92 (s, 1H, 2-H), 7.48 (br s,1H, 7-H), 7.35 (dd,J= 8.3, 1.5 Hz, 1H, 5-H), 6.94 (d,J= 16 Hz, 1H, 10-H),
6.67 (d,J= 16 Hz, 1H, 9-H), 5.10 (br s, 1H, 12-H), 5.03 (br s, 1H, 12-H), 1.98 (s, 3H, 13-H);
13C NMR
(75MHz, 293 K, CD3OD):δ= 169.0, 143.7, 139.0, 134.0, 133.8, 131.3, 130.7, 127.3, 122.1, 121.3, 116.7, 111.1,
109.9, 18.8;
HRMS (EI+) calcd for C14H13NO2
[M+] 227.0946, found 227.0936.
see
TMC-205, a new transcriptional up-regulator of SV40 promoter produced by an undentified fungus. Fermentation, isolation, physico-chemical properties, structure determination and biological activities
J Antibiot 2001, 54(8): 628
A new transcriptional up-regulator designated TMC-205 was discovered from the fermentation broth of an unidentified fungal strain TC 1630 by using an SV40 promoter-luciferase reporter assay. Based on spectroscopic analyses, its structure was determined to be (E)-6-(3-methyl-1,3-butadienyl)- H-indole-3-carboxylic acid. Expression of the luciferase activity was activated ca. 2-, 4-, and 6-fold by 1, 10, and 100 microM TMC-205, respectively. TMC-205 activated the transcriptional activity in a manner dependent on the presence of the enhancer element of SV40 in its promoter region.
Share

Shedding Light On Lung Disease Immunochemistry: Engineered antibody reduces inflammation in mice with lung condition

 Uncategorized  Comments Off on Shedding Light On Lung Disease Immunochemistry: Engineered antibody reduces inflammation in mice with lung condition
Jun 242014
 
09225-notw3-antibodycxd_17033436-350

A deadly protein is thwarted by the binding of an engineered antibody (gray) to integrin ανβ8 (binding site in red) in this computer model.
Credit: Sci. Transl. Med.

A new study reveals the key role a protein plays in chronic obstructive pulmonary disease (COPD) and provides a potential lead for treating the incurable lung disease (Sci. Transl. Med. 2014, DOI: 10.1126/scitranslmed.3008074).

[+]Enlarge

A deadly protein is thwarted by the binding of an engineered antibody (gray) to integrin ανβ8 (binding site in red) in this computer model.
Credit: Sci. Transl. Med.

09225-notw3-antibodycxd_17033436-350

A deadly protein is thwarted by the binding of an engineered antibody (gray) to integrin ανβ8 (binding site in red) in this computer model.
Credit: Sci. Transl. Med.

Stephen L. Nishimura, a professor in the pathology department at the University of California, San Francisco, and colleagues have engineered a monoclonal antibody that prevents the activation of a destructive protein in COPD mouse models and have explored in detail how the antibody binds to its target.

Share

Polyketide Synthase Secrets Revealed Structural Enzymology: Findings could aid engineering of multienzyme complexes for drug discovery

 drugs  Comments Off on Polyketide Synthase Secrets Revealed Structural Enzymology: Findings could aid engineering of multienzyme complexes for drug discovery
Jun 242014
 
09225-notw1-schematic_17033141-159

ENZYME FACTORY
During PKS biosynthesis, ACP moves to AT to pick up an extender group and then delivers it to KS. In KS’s active site, the group is added to pentaketide. ACP then takes the fused product to KR, where it is reduced. Finally, ACP offers the extended product to PKS’s next module. Active sites on enzyme domains are yellow.
Credit: Adapted from Nature

Polyketide Synthase Secrets Revealed

Structural Enzymology: Findings could aid engineering of multienzyme complexes for drug discovery
A new study solves long-standing mysteries about how bacterial natural-product-making factories are put together and how they work. The findings could accelerate efforts to engineer these workshops to produce novel bioactive agents for drug discovery.
Share

AZD 6564 in preclinical for Antifibrinolytics

 Uncategorized  Comments Off on AZD 6564 in preclinical for Antifibrinolytics
Jun 232014
 

Abstract Image

AZD 6564

ACS Med. Chem. Lett., 2014, 5 (5), pp 538–543
DOI: 10.1021/ml400526d

SYNTHESIS SUPP INFO…..http://pubs.acs.org/doi/suppl/10.1021/ml400526d/suppl_file/ml400526d_si_001.pdf

NMR PG 16/32 AS ABOVE

Figure imgf000012_0002R1 = NEOPENTYL R2=H

5-[(2R,4S)-2-(2,2-Dimethylpropyl)piperidin-4-yl]-1,2-oxazol-3(2H)-one

5-((2R,4S)-2-Neopentylpiperidin-4-yl)isoxazol-3(2H)-one

238.326

C13 H22 N2 O2

Antifibrinolytics

AstraZeneca (Innovator)

SYNTHESIS SUPP INFO…..http://pubs.acs.org/doi/suppl/10.1021/ml400526d/suppl_file/ml400526d_si_001.pdf

NMR PG 16 0F 32

……………………..

Discovery of the fibrinolysis inhibitor AZD6564, acting via interference of a protein – Protein interaction
ACS Med Chem Lett 2014, 5(5): 538

http://pubs.acs.org/doi/abs/10.1021/ml400526d

Abstract Image

A class of novel oral fibrinolysis inhibitors has been discovered, which are lysine mimetics containing an isoxazolone as a carboxylic acid isostere. As evidenced by X-ray crystallography the inhibitors bind to the lysine binding site in plasmin thus preventing plasmin from binding to fibrin, hence blocking the protein–protein interaction. Optimization of the series, focusing on potency in human buffer and plasma clotlysis assays, permeability, and GABAa selectivity, led to the discovery of AZD6564 (19) displaying an in vitro human plasma clot lysis IC50 of 0.44 μM, no detectable activity against GABAa, and with DMPK properties leading to a predicted dose of 340 mg twice a day oral dosing in humans.

SUPP INFO…..http://pubs.acs.org/doi/suppl/10.1021/ml400526d/suppl_file/ml400526d_si_001.pdf

 

Step 9: 5,((2R,4S),2,Neopentylpiperidin,4,yl)isoxazol,3(2H),one

Starting from (2R,4S),methyl 2,neopentyl,4,(3,oxo,2,3,dihydroisoxazol,5,
yl)piperidine,1,
carboxylate (0.8 g, 2.7 mmol) and following the procedure described in 15, Step8
the title
compound was obtained (0.44 g, 69 %):
1H NMR (600 MHz, DMSO,d6) δ 0.92 (s, 9H), 1.11 –1.34 (m, 3H), 1.35 – 1.46 (m, 1H), 1.79 – 1.98 (m, 2H), 2.65 – 2.93 (m, 3H),
3.03 – 3.14 (m,1H), 5.74 (s, 1H);13C NMR (101 MHz, CH4,d4) δ 177.39, 174.72, 95.42, 54.83, 49.32, 45.50,
37.13, 34.75, 31.19, 30.07, 28.06;
[α]20D+43.8 (MeOH/H2O 1:1, c = 1); HRMS calculated for[C13H23N2O2]+: 239.1759; found: 239.1753
Compounds of formula I- V may be prepared by the following route:Scheme A. Preparation of intermediatesMETHOD A

Figure imgf000015_0001

O

L C^O”

 

Figure imgf000015_0002

METHOD B

O

Figure imgf000015_0003

 

Figure imgf000015_0004

METHOD C

 

Figure imgf000016_0001

METHOD D

RIB(OR)2

 

Figure imgf000016_0002

X = Cl, Br

 

Figure imgf000016_0003

METHOD E

Figure imgf000017_0001

METHOD F

Figure imgf000017_0002

METHOD G

 

Figure imgf000018_0001

R1 = 1-methyl-1 H-tetrazol-5-yl and 2-methyl-2H-tetrazol-5-yl

Scheme B. Formation of 5-isoxazol-3-ones

°Y I ‘relative

Figure imgf000019_0001
Figure imgf000019_0002

°Y J ‘relative

Figure imgf000019_0003

………………….

http://www.google.com/patents/EP2417131A1?cl=en

Example 14

5-((2R,4S)-2-Neopentylpiperidin-4-yl)isoxazol-3(2H)-one

Step 1 : Cis-methyl 2-neopentyl-4-(3-oxo-23-dihvdroisoxazol-5-yl)piperidine-l-carboxylate The compound was prepared as described in Example 1, Step 2 starting from cis-methyl 4-(3- ethoxy-3-oxopropanoyl)-2-neopentylpiperidine-l -carboxylate (2.68 g, 8.19 mmol) which resulted in cis-methyl 2-neopentyl-4-(3-oxo-2,3-dihydroisoxazol-5-yl)piperidine-l- carboxylate (1.60 g, 66 %) : IH NMR (400 MHz, cdcl3) δ 0.89 (s, 9H), 1.18 (dd, IH), 1.45 (dd, IH), 1.80 – 1.92 (m, 2H), 1.97 – 2.17 (m, 2H), 2.94 – 3.02 (m, IH), 3.11 – 3.23 (m, IH), 3.71 (s, 3H), 3.88 – 3.99 (m, IH), 4.22 – 4.32 (m, IH), 5.72 (s, IH); m/z (MH+) 297.

Step 2: (2R,4S)-Methyl 2-neopentyl-4-(3-oxo-2,3-dihvdroisoxazol-5-yl)piperidine-l- carboxylate

Following the procedure described in Example 1, Step 3, racemic cis-methyl 2-neopentyl-4- (3-oxo-2,3-dihydroisoxazol-5-yl)piperidine-l -carboxylate (1.60 g, 5.4 mmol) was subjected to chiral separation using Chiralcel IC mobile phase heptane/IP A/FA 60/40/0.1 which resulted in (2R,4S)-methyl 2-neopentyl-4-(3-oxo-2,3-dihydroisoxazol-5-yl)piperidine-l-carboxylate (0.8 g, 2.7 mmol).

Step 3: 5-((2R,4S)-2-Neopentylpiperidin-4-yl)isoxazol-3(2H)-one

5 Starting from (2R,4S)-methyl 2-neopentyl-4-(3-oxo-2,3-dihydroisoxazol-5-yl)piperidine-l- carboxylate (0.8 g, 2.7 mmol) and following the procedure described in Example 1, Step 4 the title compound was obtained (0.44 g, 69 %): 1H NMR (600 MHz, DMSO-d6) δ 0.89 (s, 9H), 1.18 (m, 2H), 1.50 (m, 2H), 1.82-1.90 (m, 2H), 2.70-2.85 (m, 3H), 3.08 (m, IH), 5.71 (s, IH). [α]20 D +43.8 (MeOH/H2O 1:1, c = 1); HRMS calculated for [C13H23N2O2]+: 239.1759; found: 10 239.1753.

 

ANTHONY MELVIN CRASTO

THANKS AND REGARD’S
DR ANTHONY MELVIN CRASTO Ph.D

amcrasto@gmail.com

MOBILE-+91 9323115463
GLENMARK SCIENTIST ,  INDIA
web link
http://anthonycrasto.jimdo.com/

Congratulations! Your presentation titled “Anthony Crasto Glenmark scientist, helping millions with websites” has just crossed MILLION views.
アンソニー     安东尼   Энтони    안토니     أنتوني
join my process development group on google
you can post articles and will be administered by me on the google group which is very popular across the world
LinkedIn group
 
blogs are
 
shark

========================

Share

Black Fungus Health Benefits (Anticancer Remedy)

 cancer  Comments Off on Black Fungus Health Benefits (Anticancer Remedy)
Jun 212014
 

Black fungus is a very common type of edible mushroom which is found in Nigeria and other parts of the world. It grows on trees mostly in the rural areas due to the vast untapped vegetation found there. –

See more at: http://www.dobbyssignature.com/2012/06/black-fungus-health-benefits-anticancer.html#sthash.MrRk0WH7.dpuf

http://www.dobbyssignature.com/2012/06/black-fungus-health-benefits-anticancer.html

Share

A Glass of Wine Against Dental Caries?

 Uncategorized  Comments Off on A Glass of Wine Against Dental Caries?
Jun 202014
 

thumbnail image: A Glass of Wine Against Dental Caries?

A Glass of Wine Against Dental Caries?

Moderate concentrations of red wine inhibit the growth of pathogens causing dental caries

Read more

http://www.chemistryviews.org/details/news/6286181/A_Glass_of_Wine_Against_Dental_Caries.html

 

 

 

 

 

 

 

 

BRAZIL WORLDCUP WEEK 2014

 

 

Share

Worldwide Hepatitis C Market: CV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast 2018

 Uncategorized  Comments Off on Worldwide Hepatitis C Market: CV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast 2018
Jun 192014
 
WhaTech Channel: Reports Industrial
Published: Wednesday, 18 June 2014 20:34
Submitted by Market Research WhaTech Premium
News from: RnR Market Research

Hepatitis C market by 2018 is expected to grow more than 3 times from its current market size of 2012. Hepatitis C virus (HCV) infection is a complex public health problem, characterized by a high prevalence of chronic infection, an increasing burden of HCV-associated disease, low rates of testing, treatment and the prospect of increasing incidence associated with the epidemic of injection drug use.

http://www.whatech.com/members-news/reports-industrial/22195-worldwide-hepatitis-c-market-cv-drugs-clinical-trials-hepatitis-c-pipeline-drugs-sales-forecast-2018

Hepatitis C Market Overview

Hepatitis C is a leading cause of chronic liver disease, end-stage cirrhosis and liver cancer. Because of the slow progression and asymptomatic character of the infection, many people are unaware of having it. As a consequence, the infection is often diagnosed at a late stage when treatment options are limited. As no effective vaccine against the Hepatitis C virus (HCV) has been discovered so far the market is driven by therapeutics. The increase in the prevalence of the disease and the availability of new first-in-class therapies with better safety and efficacy profiles are expected to drive the growth of the HCV market. The growth in HCV drugs market is primarily attributed to high unmet need in the market which is expected to be fulfilled by strong pipeline candidates. Low levels of awareness and knowledge about HCV have been identified as a formidable challenge to prevention and care.

Complete report is available @ http://www.rnrmarketresearch.com/hepatitis-c-market-forecast-hcv-drugs-clinical-trials-hepatitis-c-pipeline-drugs-sales-forecast-worldwide-market-report.html .

Renub Research study titled “Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast – Worldwide” provides a comprehensive assessment of the fast-evolving, high-growth of Hepatitis sector. This 164 page report with 25 Figures and 2 Tables studies the Hepatitis C Drug Market Landscape. This report contains 7 chapters.

  • Hepatitis C Drugs Market & Forecast (Chapter 2)
  • Hepatitis C Approved Drugs Sales & Forecast (Chapter 3)
  • Hepatitis C Deals & Acquisitions (Chapter 4)
  • Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase III) (Chapter 5)
  • Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase II) (Chapter 6)
  • Hepatitis C – Pipeline Drugs Sales Forecast (Chapter 7)

Hepatitis C – Approved Drugs sales & Forecast Analysis (To 2016) (Chapter No. 3)

  1. Pegasys
  2. Pegintron
  3. Incivek
  4. Victrelis

Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase III) (Chapter No. 5)

  • Simeprevir (TMC 435) (Company: Janssen Pharmaceutical)
  • Faldaprevir (BI 201335) (Company: Boerhinger Ingelheim)
  • Asunaprevir (BMS-650032) (Company: Bristol-Myers Squibb)
  • PEG-Interferon Lambda (Company: Bristol-Myers Squibb)
  • Sofosbuvir (PSI-7977 or GS-7977) (Company: Gilead Sciences)
  • Daclatasvir (BMS-790052) (Company: Bristol-Myers Squibb)
  • BI-207127 (Company: Boerhinger Ingelheim)
  • ABT-450/r (Ritonavir) (Company: Abbott Laboratories)
  • ABT-267 (Company: Abbott Laboratories)
  • ABT-072/333 (Company: Abbott Laboratories)
  • Alisporivir (Company: Novartis)

Purchase a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=186104 .

Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase II) (Chapter No. 6)

  • Mericitabine (RG-7128) (Company: Roche)
  • Danoprevir/r (Ritonavir) (RG7227) (Company: Roche)
  • GS-9256 (Company: Gilead Sciences)
  • GS-9451 (Company: Gilead Sciences)
  • MK-5172 (Company: Merck)
  • Sovaprevir (ACH-1625) (Company: Achillion)
  • IDX-320 (Company: Idenix)
  • MK-8742 (Company: Merck)
  • ACH-3102 (Company: Achillion Pharmaceuticals, Inc)
  • IDX-719 (Company: Idenix)
  • PPI-668 (Company: Presidio Pharmaceuticals)
  • Setrobuvir (ANA-598) (Company: Roche)
  • VX-222 (Company: Vertex Pharmaceuticals)
  • GS-9669 (Company: Gilead Sciences)
  • GS-9190 (Tegobuvir) (Company: Gilead Sciences)
  • BMS-791325 (Company: Bristol-Myers Squibb)

Hepatitis C – Pipeline Drugs Sales Forecast (Chapter 7)

  • Simeprevir (TMC 435)
  • Faldaprevir (BI 201335) (Boerhinger Ingelheim)
  • Asunaprevir (BMS-650032)
  • Sofosbuvir (PSI-7977 or GS-7977)
  • Daclatasvir (BMS-790052)
  • ABT-450/r (Ritonavir)
  • ABT-072/333
  • Alisporivir
  • Mericitabine (RG-7128)
  • Danoprevir (RG7227)
  • GS-9256
  • Setrobuvir (ANA-598)
  • VX-222
  • GS-9190 (Tegobuvir)
  • BMS-791325

Data Sources

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts.

Primary sources include industry surveys and telephone interviews with industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.

News From

RnR Market Research
Share
Follow

Get every new post on this blog delivered to your Inbox.

Join other followers: